GlassScriptPhysician profile
Grace A Mazzarella
NPI 1861865677
$9,709.44
in general payments reported to CMS, 2019-2025
31 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,277 · 2022: $1,861 · 2023: $1,860 · 2024: $2,404 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,471 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,471.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,573.06 | 2021-2025 | |
| Ucb, INC. | $856.24 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $635.02 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $607.66 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $567.46 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $497.00 | 2023-2025 | Sotyktu |
| Amgen INC. | $446.03 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $413.91 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $395.32 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $395.05 | 2021-2025 | |
| Incyte Corporation | $393.17 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $375.49 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $329.52 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $318.09 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $295.06 | 2021-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $241.80 | 2021-2025 | Aklief, Nemluvio, Epsolay |
| Almirall LLC | $240.42 | 2022-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.30 | 2021-2024 | Spevigo, Cyltezo |
| Mayne Pharma Commercial LLC | $169.31 | 2021-2025 | |
| Pfizer INC. | $156.60 | 2021-2025 | |
| Botanix Sb INC | $94.23 | 2025 | Sofdra |
| Epi Health, LLC | $87.01 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $65.91 | 2021 | |
| Verrica Pharmaceuticals INC. | $64.77 | 2023-2025 | Ycanth |
| Journey Medical Corporation | $61.24 | 2022-2025 | |
| Sebela Pharmaceuticals INC. | $59.40 | 2021-2023 | Naftin |
| Biofrontera INC. | $58.37 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $43.97 | 2025 | |
| Lnhc, INC | $42.02 | 2025 | Zelsuvmi |
| Sandoz INC. | $16.12 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Mazzarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.